Veeva Systems Inc. (VEEV) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $162.31 (+0.12%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 13, 2026 | Adam Hotchkiss | Goldman Sachs | $215.00 | +32.5% |
| Dec 4, 2025 | Craig Hettenbach | Morgan Stanley | $222.00 | +36.8% |
| Nov 25, 2025 | Stan Berenshteyn | Wells Fargo | $333.00 | +105.2% |
| Nov 24, 2025 | David Windley | Jefferies | $330.00 | +103.3% |
| Aug 28, 2025 | Brent Bracelin | Piper Sandler | $355.00 | +118.7% |
| Aug 28, 2025 | Brian Peterson | Raymond James | $340.00 | +109.5% |
| Aug 28, 2025 | Saket Kalia | Barclays | $330.00 | +103.3% |
| May 29, 2025 | Brent Bracelin | Piper Sandler | $325.00 | +100.2% |
| Jan 23, 2025 | Gabriela Borges | Goldman Sachs | $200.00 | +23.2% |
| Dec 19, 2024 | Jeff Garro | Stephens | $280.00 | +72.5% |
| Sep 20, 2024 | Ken Wong | Oppenheimer | $230.00 | +41.7% |
| Sep 3, 2024 | Joe Meares | Truist Financial | $207.00 | +27.5% |
| Aug 29, 2024 | Brad Sills | Bank of America Securities | $240.00 | +47.9% |
| Aug 29, 2024 | Tyler Radke | Citigroup | $281.00 | +73.1% |
| Aug 27, 2024 | Tyler Radke | Citigroup | $273.00 | +68.2% |
| Aug 26, 2024 | Karl Keirstead | UBS | $215.00 | +32.5% |
| Jul 9, 2024 | David Larsen | BTIG | $240.00 | +47.9% |
| Jun 13, 2024 | Joe Meares | Truist Financial | $197.00 | +21.4% |
| May 31, 2024 | David Grossman | Stifel Nicolaus | $210.00 | +29.4% |
| May 31, 2024 | David Hynes | Canaccord Genuity | $210.00 | +29.4% |
Top Analysts Covering VEEV
VEEV vs Sector & Market
| Metric | VEEV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.38 | 2.24 | 2.40 |
| Analyst Count | 34 | 8 | 19 |
| Target Upside | +47.4% | +11475.0% | +17.1% |
| P/E Ratio | 28.93 | 3.88 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-31 | $3.56B | $3.60B | $3.61B | 21 |
| 2027-04-30 | $958M | $965M | $983M | 14 |
| 2027-07-31 | $992M | $999M | $1.02B | 11 |
| 2027-10-31 | $1.02B | $1.02B | $1.04B | 8 |
| 2028-01-31 | $1.05B | $1.05B | $1.07B | 7 |
| 2028-04-30 | $1.10B | $1.11B | $1.13B | 13 |
| 2028-07-31 | $1.14B | $1.15B | $1.17B | 10 |
| 2028-10-31 | $1.17B | $1.18B | $1.20B | 7 |
| 2029-01-31 | $1.20B | $1.21B | $1.23B | 8 |
| 2030-01-31 | $5.11B | $5.17B | $5.25B | 7 |
| 2031-01-31 | $5.81B | $5.88B | $5.97B | 9 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-31 | $8.43 | $8.86 | $9.01 | 18 |
| 2027-04-30 | $2.35 | $2.38 | $2.43 | 13 |
| 2027-07-31 | $2.43 | $2.45 | $2.51 | 10 |
| 2027-10-31 | $2.51 | $2.53 | $2.59 | 7 |
| 2028-01-31 | $2.55 | $2.57 | $2.63 | 8 |
| 2028-04-30 | $2.72 | $2.75 | $2.81 | 14 |
| 2028-07-31 | $2.81 | $2.83 | $2.90 | 11 |
| 2028-10-31 | $2.93 | $2.96 | $3.03 | 8 |
| 2029-01-31 | $2.97 | $2.99 | $3.07 | 7 |
| 2030-01-31 | $12.98 | $13.16 | $13.43 | 1 |
| 2031-01-31 | $15.08 | $15.29 | $15.60 | 2 |
Frequently Asked Questions
What is the analyst consensus for VEEV?
The consensus among 34 analysts covering Veeva Systems Inc. (VEEV) is Buy with an average price target of $280.10.
What is the highest price target for VEEV?
The highest price target for VEEV is $355.00, set by Brent Bracelin at Piper Sandler on 2025-08-28.
What is the lowest price target for VEEV?
The lowest price target for VEEV is $197.00, set by Joe Meares at Truist Financial on 2024-06-13.
How many analysts cover VEEV?
34 analysts have issued ratings for Veeva Systems Inc. in the past 12 months.
Is VEEV a buy or sell right now?
Based on 34 analyst ratings, VEEV has a consensus rating of Buy (2.38/5) with a +47.4% upside to the consensus target of $280.10.
What are the earnings estimates for VEEV?
Analysts estimate VEEV will report EPS of $8.86 for the period ending 2027-01-31, with revenue estimated at $3.60B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.